Emerging ctDNA detection strategies in clinical cancer theranostics
Abstract Circulating tumor DNA (ctDNA) is naked DNA molecules shed from the tumor cells into the peripheral blood circulation. They contain tumor‐specific gene mutations and other valuable information. ctDNA is considered to be one of the most significant analytes in liquid biopsies. Over the past d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2023-11-01
|
| Series: | Smart Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/SMMD.20230031 |
| _version_ | 1797372761582075904 |
|---|---|
| author | Kexin Yi Xiaoju Wang Sergey K. Filippov Hongbo Zhang |
| author_facet | Kexin Yi Xiaoju Wang Sergey K. Filippov Hongbo Zhang |
| author_sort | Kexin Yi |
| collection | DOAJ |
| description | Abstract Circulating tumor DNA (ctDNA) is naked DNA molecules shed from the tumor cells into the peripheral blood circulation. They contain tumor‐specific gene mutations and other valuable information. ctDNA is considered to be one of the most significant analytes in liquid biopsies. Over the past decades, numerous researchers have developed various detection strategies to perform quantitative or qualitative ctDNA analysis, including PCR‐based detection and sequencing‐based detection. More and more studies have illustrated the great value of ctDNA as a biomarker in the diagnosis, prognosis and heterogeneity of tumor. In this review, we first outlined the development of digital PCR (dPCR)‐based and next generation sequencing (NGS)‐based ctDNA detection systems. Besides, we presented the introduction of the emerging ctDNA analysis strategies based on various biosensors, such as electrochemical biosensors, fluorescent biosensors, surface plasmon resonance and Raman spectroscopy, as well as their applications in the field of biomedicine. Finally, we summarized the essentials of the preceding discussions, and the existing challenges and prospects for the future are also involved. |
| first_indexed | 2024-03-08T18:39:31Z |
| format | Article |
| id | doaj.art-00598fbc7218423ebca4ce3d80736ea3 |
| institution | Directory Open Access Journal |
| issn | 2751-1871 |
| language | English |
| last_indexed | 2024-03-08T18:39:31Z |
| publishDate | 2023-11-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | Smart Medicine |
| spelling | doaj.art-00598fbc7218423ebca4ce3d80736ea32023-12-29T08:08:01ZengWiley-VCHSmart Medicine2751-18712023-11-0124n/an/a10.1002/SMMD.20230031Emerging ctDNA detection strategies in clinical cancer theranosticsKexin Yi0Xiaoju Wang1Sergey K. Filippov2Hongbo Zhang3Pharmaceutical Sciences Laboratory Åbo Akademi University Turku FinlandPharmaceutical Sciences Laboratory Åbo Akademi University Turku FinlandDWI‐Leibniz Institute for Interactive Materials e. V. Aachen GermanyPharmaceutical Sciences Laboratory Åbo Akademi University Turku FinlandAbstract Circulating tumor DNA (ctDNA) is naked DNA molecules shed from the tumor cells into the peripheral blood circulation. They contain tumor‐specific gene mutations and other valuable information. ctDNA is considered to be one of the most significant analytes in liquid biopsies. Over the past decades, numerous researchers have developed various detection strategies to perform quantitative or qualitative ctDNA analysis, including PCR‐based detection and sequencing‐based detection. More and more studies have illustrated the great value of ctDNA as a biomarker in the diagnosis, prognosis and heterogeneity of tumor. In this review, we first outlined the development of digital PCR (dPCR)‐based and next generation sequencing (NGS)‐based ctDNA detection systems. Besides, we presented the introduction of the emerging ctDNA analysis strategies based on various biosensors, such as electrochemical biosensors, fluorescent biosensors, surface plasmon resonance and Raman spectroscopy, as well as their applications in the field of biomedicine. Finally, we summarized the essentials of the preceding discussions, and the existing challenges and prospects for the future are also involved.https://doi.org/10.1002/SMMD.20230031biosensorcancer theranosticscirculating tumor DNAdigital PCRnext generation sequencing |
| spellingShingle | Kexin Yi Xiaoju Wang Sergey K. Filippov Hongbo Zhang Emerging ctDNA detection strategies in clinical cancer theranostics Smart Medicine biosensor cancer theranostics circulating tumor DNA digital PCR next generation sequencing |
| title | Emerging ctDNA detection strategies in clinical cancer theranostics |
| title_full | Emerging ctDNA detection strategies in clinical cancer theranostics |
| title_fullStr | Emerging ctDNA detection strategies in clinical cancer theranostics |
| title_full_unstemmed | Emerging ctDNA detection strategies in clinical cancer theranostics |
| title_short | Emerging ctDNA detection strategies in clinical cancer theranostics |
| title_sort | emerging ctdna detection strategies in clinical cancer theranostics |
| topic | biosensor cancer theranostics circulating tumor DNA digital PCR next generation sequencing |
| url | https://doi.org/10.1002/SMMD.20230031 |
| work_keys_str_mv | AT kexinyi emergingctdnadetectionstrategiesinclinicalcancertheranostics AT xiaojuwang emergingctdnadetectionstrategiesinclinicalcancertheranostics AT sergeykfilippov emergingctdnadetectionstrategiesinclinicalcancertheranostics AT hongbozhang emergingctdnadetectionstrategiesinclinicalcancertheranostics |